Key Highlights

  • 13.9 million is the USD net loss Prelude Therapeutics Incorporated (NASDAQ:PRLD) reported for the second quarter of 2026, or USD 0.14 per share, against USD 31.2 million, or USD 0.41 per share, a year earlier.
  • 155.2 million is the USD amount of cash, cash equivalents, restricted cash and marketable securities held on June 30, 2026, which management expects to fund operations into the second quarter of 2028.
  • 5.7 million is the USD Revenue recorded in the second quarter of 2026, compared with none a year earlier, while total operating expenses fell to USD 21.2 million from USD 32.2 million.
  • 4 is the quarter of 2026 in which Phase 1 development of PRT13722, an oral KAT6A degrader for HR+ breast cancer, is expected to begin, pending IND clearance.

What Investors Expect From Prelude Therapeutics Incorporated (NASDAQ:PRLD) on November 16, 2026

The clinical-stage oncology company is scheduled to report third quarter 2026 results on November 16, 2026. The reference point is the second quarter, when the net loss narrowed by about 55.4%, calculated, to USD 13.9 million from USD 31.2 million. Revenue of USD 5.7 million had no prior-year equivalent, and deferred revenue stood at USD 25.2 million on June 30, 2026. Weighted average shares outstanding rose to 98,388,593 from 75,993,941, which helped lower the loss per share to USD 0.14 from USD 0.41.

The Rationale: Last Reported Quarter and Management Outlook for Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Research and development expense fell to USD 16.1 million from USD 25.8 million, and general and administrative expense declined to USD 5.0 million from USD 6.4 million. The loss from operations was USD 15.5 million against USD 32.2 million, and other income, net, was USD 1.5 million against USD 1.0 million. Management cleared the IND for PRT12396, a mutant-selective JAK2V617F inhibitor, in February 2026 and is enrolling Phase 1 patients in polycythemia vera and myelofibrosis. That program is subject to an exclusive option agreement with Incyte announced in November 2025.

Valuation, Liquidity and Risks for Prelude Therapeutics Incorporated (NASDAQ:PRLD)

The Balance Sheet at June 30, 2026 showed cash and cash equivalents of USD 26.3 million, marketable securities of USD 125.4 million, total Assets of USD 189.4 million, total liabilities of USD 55.6 million and stockholders' Equity of USD 133.7 million. The accumulated Deficit was USD 707.4 million. The company has not issued numeric financial guidance. Risks include early-stage clinical development, dependence on IND clearance for PRT13722, the uncertain exercise of the Incyte option, collaboration revenue that may not recur, and the likelihood of further Capital needs beyond the second quarter of 2028.

Where Things Stand

Prelude Therapeutics Incorporated (NASDAQ:PRLD) enters its November 16, 2026 report with a leaner cost base and a longer funding horizon than a year ago. Quarterly operating expenses of USD 21.2 million compare with USD 32.2 million, and cash of USD 155.2 million is projected to last into the second quarter of 2028. Investors will look for progress on the Phase 1 trial of the JAK2V617F inhibitor, an update on IND clearance and the planned fourth quarter start for the KAT6A degrader PRT13722, any news on the Incyte option, and the trajectory of revenue after the USD 5.7 million recorded in the second quarter.